Imlunestrant单药或联合Abemaciclib治疗ER+、HER2-晚期乳腺癌:III期随机EMBER-3研究的中国亚组分析。
完整摘要 · 中文译文
背景:Imlunestrant是一种下一代口服选择性雌激素受体降解剂。在雌激素受体阳性(ER+)、人表皮生长因子受体2阴性(HER2-)晚期乳腺癌患者中,全球EMBER-3研究显示,在携带雌激素受体1突变(ESR1m)的患者中,imlunestrant单药治疗相比标准治疗(SOC)氟维司群或依西美坦,在无进展生存期(PFS)方面取得了具有统计学意义和临床意义的改善;在所有患者中,无论ESR1m状态如何,imlunestrant-阿贝西利联合治疗相比imlunestrant单药治疗亦取得改善。 目的:我们旨在展示全球III期EMBER-3研究中国队列及中国扩展队列的中国人群数据。 方法:年龄≥18岁、患有ER+、HER2-晚期乳腺癌且既往接受过芳香化酶抑制剂±细胞周期蛋白依赖性激酶4/6抑制剂治疗的成人患者,按1:1:1随机分配接受imlunestrant、SOC或imlunestrant-阿贝西利治疗。主要终点为研究者评估的所有患者及携带ESR1m患者中imlunestrant相比SOC的PFS,以及研究者评估的所有患者中imlunestrant-阿贝西利相比imlunestrant的PFS。次要终点包括总生存期和安全性。患者报告结局为探索性终点。 结果:2022年11月至2025年4月期间,来自22个中心的83例中国患者被随机分配至imlunestrant组(n = 24)、SOC组(n = 29)或imlunestrant-阿贝西利组(n = 30)。ESR1m检出率分别为25%(n = 6)、7%(n = 2),以及20%(n = 6)的患者。在接受imlunestrant对比标准治疗(SOC)的ESR1m患者中,中位无进展生存期(PFS)为5.5个月对比2.7个月(风险比,0.36;95%置信区间0.05-2.59)。在接受imlunestrant-abemaciclib对比imlunestrant的ESR1m患者中,中位PFS为15.7个月对比5.5个月(风险比,0.43;95%置信区间0.11-1.75);在接受这些治疗的所有中国患者中,中位PFS为7.4个月对比5.6个月(风险比,1.04;95%置信区间0.55-1.98)。以imlunestrant为基础的方案在中国患者中耐受良好,相对于全球人群未发现新的安全性信号。患者报告结局总体维持,而大多数(79%)接受氟维司群治疗的患者报告在治疗期间任何时候出现注射部位疼痛或肿胀。 结论:中国人群的研究结果与全球EMBER-3数据总体一致,提示以imlunestrant为基础的治疗作为中国ER+、HER2-晚期乳腺癌患者的口服靶向治疗选择具有潜在临床获益。 临床试验注册:ClinicalTrials.gov,NCT04975308(首次发布:2021年7月23日)。 对激素雌激素产生反应而生长且不具有高水平人表皮生长因子受体2(HER2)蛋白的乳腺癌是最常见的乳腺癌类型,称为雌激素受体阳性(ER+)、HER2−乳腺癌。该类型乳腺癌的主要治疗方法之一是激素治疗(也称为内分泌治疗)。这些 药物要么降低体内雌激素的量,要么阻止雌激素到达癌细胞。激素治疗通常与靶向治疗联合给予,包括细胞周期蛋白依赖性激酶4/6抑制剂,其可减缓癌细胞生长。然而,癌症可能停止对激素治疗产生应答并重新开始生长。其主要原因之一是一个名为ESR1的基因发生改变(突变),该基因编码雌激素受体蛋白。Imlunestrant是一种与雌激素受体结合、阻止雌激素与其结合并降解雌激素受体的药物。基于III期EMBER-3试验的主要结果,该药已在美国、欧洲、中国及其他国家获批用于乳腺癌具有ESR1突变的患者。本分析评估了EMBER-3中中国患者使用imlunestrant的情况。这些患者的结果与整个试验的结果总体一致。Imlunestrant单用或与一种名为阿贝西利的细胞周期蛋白依赖性激酶4/6抑制剂联用,可能比标准治疗对患者更有帮助,且副作用可控。由于参与的中国患者数量较少,这些发现提示可能存在获益,而非证明存在获益。
完整摘要 · 英文原文
BACKGROUND: Imlunestrant is a next-generation, oral, selective estrogen receptor degrader. In patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, the global EMBER-3 study demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) with imlunestrant monotherapy versus standard of care (SOC) fulvestrant or exemestane in patients with an estrogen receptor 1 mutation (ESR1m), and imlunestrant-abemaciclib combination treatment versus imlunestrant monotherapy in all patients, regardless of the ESR1m. OBJECTIVE: We aimed to present data of the Chinese population from the China cohort of the global phase III EMBER-3 study, and the Chinese expansion cohort. METHODS: Adults (aged ≥ 18 years) with ER+, HER2- advanced breast cancer, and prior treatment with aromatase inhibitors ± cyclin-dependent kinase 4/6 inhibitors, were randomly assigned (1:1:1) to receive imlunestrant, SOC, or imlunestrant-abemaciclib. Primary endpoints were investigator-assessed PFS with imlunestrant versus SOC in all patients and in those harboring an ESR1m, and investigator-assessed PFS with imlunestrant-abemaciclib versus imlunestrant in all patients. Secondary endpoints included overall survival, and safety. Patient-reported outcomes were an exploratory endpoint. RESULTS: Between November 2022 and April 2025, 83 Chinese patients from 22 centers were randomized to imlunestrant (n = 24), SOC (n = 29), or imlunestrant-abemaciclib (n = 30). An ESR1m was detected in 25% (n = 6), 7% (n = 2), and 20% (n = 6) of patients, respectively. In patients with an ESR1m receiving imlunestrant versus SOC, median PFS was 5.5 versus 2.7 months (hazard ratio, 0.36; 95% confidence interval 0.05-2.59). Among patients with an ESR1m receiving imlunestrant-abemaciclib versus imlunestrant, median PFS was 15.7 versus 5.5 months (hazard ratio, 0.43; 95% confidence interval 0.11-1.75); among all Chinese patients receiving these treatments, median PFS was 7.4 versus 5.6 months (hazard ratio, 1.04; 95% confidence interval 0.55-1.98). Imlunestrant-based regimens were well tolerated in Chinese patients, with no new safety signals relative to the global population. Patient-reported outcomes were generally maintained, while the majority (79%) of patients receiving fulvestrant reported injection-site pain or swelling at any time on treatment. CONCLUSIONS: Findings from the Chinese population are generally consistent with global EMBER-3 data and suggest the potential clinical benefit of imlunestrant-based therapy as an oral targeted treatment option for Chinese patients with ER+, HER2- advanced breast cancer. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT04975308 (first posted: 23 July, 2021). Breast cancer that grows in response to the hormone estrogen and that does not have high levels of a protein called human epidermal growth factor receptor 2 (HER2) is the most common type of breast cancer, called estrogen receptor-positive (ER+), HER2− breast cancer. One of the main treatment approaches for this type of breast cancer is hormone therapy (also called endocrine therapy). These medicines either lower the amount of estrogen in the body or stop estrogen from reaching the cancer cells. Hormone therapy is often given with targeted therapies, including cyclin-dependent kinase 4/6 inhibitors, which slow cancer cell growth. However, cancer may stop responding to hormone therapy and start to grow again. One of the main reasons for this is a change (mutation) in a gene called ESR1, which encodes the estrogen receptor protein. Imlunestrant is a medicine that binds to the estrogen receptor, preventing estrogen from binding to it, and breaks down the estrogen receptor. It is approved in the USA, Europe, China, and other countries for patients whose breast cancer has an ESR1 mutation, based on the main results of the phase III EMBER-3 trial. This analysis assessed imlunestrant in Chinese patients from EMBER-3. The results in these patients were generally consistent with the results for the trial as a whole. Imlunestrant, taken on its own or together with a cyclin-dependent kinase 4/6 inhibitor called abemaciclib, may help patients more than standard treatment does and side effects were manageable. Because only a small number of patients from China took part, these findings point to a possible benefit rather than proving one.